Application of Sr/ Rb generator in neurooncology.

Introduction: The applicability of "Rubidium Chloride, Rb from Generator" radiopharmaceutical for brain tumors (BT) diagnostics is demonstrated on the basis of the application experience of the radiopharmaceutical in neurooncology.

Experimental: A total of 21 patients with various brain tumors and nonneoplastic abnormal brain masses were investigated.

Results And Discussions: The results of the imaging and differential diagnostics of malignant and benign tumors, nonneoplastic abnormal brain masses and lesions revealed the prevalence of high uptake of the radiopharmaceutical in the malignant tumors in comparison with benign glioma and arteriovenous malformations in which Rb-chloride accumulates in the vascular phase but does not linger further.

[18F-FDG positron emission tomography in the diagnosis and staging of marginal zone non-Hodgkin lymphomas].

Objective: To investigate the diagnostic value of 18F-FDG positron emission tomography (PET) in the diagnosis and staging of marginal zone non-Hodgkin lymphomas (NHLs).

Material And Methods: Twenty-four patients with new-onset NHLs were examined. Extranodal MALT lymphoma, splenic marginal zone lymphoma (MZL), and nodal MZL lymphoma were diagnosed in 18, 3, and 3 patients, respectively.

[Differential diagnosis of brain gliomas by positron emission tomography using various radiopharmaceuticals].

Objective: To comparatively study the diagnostic capabilities of positron emission tomography (PET) with various tumorotropic radiopharmaceuticals (TRPs) in detecting malignant brain gliomas (BG) and estimating their degree.

Material And Methods: One hundred and fourteen patients, including 47 with histologically verified glioblastoma multiforme (GBM), 27 with anaplastic astrocytoma (AA), 23 with benign astrocytoma (BA), and 17 with postoperative cysts, were examined. PET was performed using TRPs: 18F-fluorodesoxyglucose (18F-FDG), 11C-sodium butyrate (11C-SB), 11C-L-methionine (11C-MET), and 11C-choline (11C-COL).

[Prognostic value of 18F-FDG positron emission tomography in the early evaluation of the efficiency of treatment in patients with non-Hodgkin lymphomas].

Objective: To define the role of 18F-FDG positron emission tomography (PET) performed after 2-3 chemotherapy cycles in the prediction of disease prognosis and to identify a group of patients requiring more intensive treatment.

Material And Methods: Seventy-one patients with non-Hodgkin lymphoma of different histological types were examined. PET was carried out at different stages of diagnosis and primary treatment in the patients.

[First experience of using positron emission tomography with 11C-choline in prostate cancer (PC)].

Introduction into clinical practice of combined positron emission technology and computer tomography (PET/CT) allows in one study to identify structural and functional abnormalities. The study involves 32 patients who underwent PET/CT with "C-choline, including 5 patients with prostate cancer (PC), 3--with chronic prostatitis and 24--with biochemical PC recurrence. PET/CT with 11C-choline has a high diagnostic efficacy in detection of local recurrence and PC metastases in patients with biochemical PC recurrence.